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The Coronavirus Disease 2019 (COVID-19) pandemic has affected over 165 million people and
caused

the

death

of

3.4

million

worldwide

(up

to

May

20,

2021)

(https://coronavirus.jhu.edu/map.html), becoming a serious problem of global public health and
the worst epidemic in the last century, after the pandemic 1918 influenza. Researchers
worldwide are trying to find valuable drugs against the Severe Acute Respiratory Syndrome
coronavirus 2 (SARS-CoV-2). Some of them focused as antivirals, others targeted in other ways

of

(e.g. immunomodulation) to relieve the symptoms of the infected patients and help lower the

ro

death toll throughout the world. Unfortunately, there is a lack of effective drugs to manage

re

-p

COVID-19.

lP

The hopeful and long-awaited development of vaccines and the approval of their use in humans

na

is a fact. The time consuming that it will take to achieve herd immunity due to waiting for the
availability and distribution of the vaccines is a reality in full swing and shows significant health

ur

inequalities. Vaccines with up to 95% of efficacy and effectiveness have been developed and

Jo

approved by the Food and Drug Administration (FDA), USA. Worldwide, 1.55 billion vaccine
doses have been administered (up to May 20, 2021) (https://coronavirus.jhu.edu/map.html).
However, it is unknown if the development of post-infection immunity detected confers
medium-long term protection and the importance of mucosal immunity to protect against
infection is still a matter of concern [1]. The effectiveness of a vaccine depends in part on its
ability to induce a defensive immune response. Nevertheless, severe reactions have been
observed in vaccine development for other respiratory viruses, including SARS-CoV [2],
probably produced by vaccine-induced antibodies that facilitate viral replication [3]; or by a
predominant cellular Th2 response that accelerates the tissue damage produced by the disease

3
[4]. This reaction is of vital importance in the case of SARS-CoV-2 since the immune response
in the form of a cytokine storm has been associated with severity [5].

A potential threat to patients with COVID-19 in helminths endemic areas (most of the tropical
and subtropical areas of developing countries) is the systemic immunomodulatory effects of
these parasites [6,7], through protein secretion [8] and by alteration of the intestinal microbiome

of

[9], that may influence the severity of other infections. However, some authors consider this

-p

ro

could be protective [10].

re

The possible implications of the immune-regulatory role of helminth intestinal infections in

lP

humans co-infected by SARS-CoV-2 and its effect on the viral disease outcome and COVID-19

na

vaccines efficacy must be considered carefully using them in endemic helminth areas, in terms of
more studies to understand this relationship. The individuals infected with helminths before

ur

being affected by SARS-CoV-2 are responding to the parasite infections by a specific Th2 type

Jo

innate and adaptive immune responses. The Th2 pattern cytokines predominate in long-term
helminth infected individuals [11]. The co-infected host needs to control the viral infection by a
robust Th1 type lung microenvironment in the initial stages of SARS-CoV-2 [12]. Helminths
modified intestinal microbiome can modulate host immune response. It is not well-defined if the
interaction between helminth-microbiota will promote susceptibility or protection in the lungs.
However, the generation of a tolerogenic and anti-inflammatory environment could stimulate
less immune response and more susceptibility to co-infections [13].

4
In helminth-infected individuals, the immunomodulation of the innate and adaptive immune
response characterized by a deviation to a Th2 pattern could enhance viral replication of SARSCoV-2 [11]. The significant case fatality rate caused by COVID-19, especially in certain
countries, is produced by the uncontrolled innate immune response and destructive
inflammation. Co-infections can modulate the host immunological outcome, and a range of
responses can be observed during all clinical phases of COVID-19. The clinical resolution can be

of

affected by different cofactors dependent on the virus, helminths, and the host, including their

ro

immunogenetic profile. Helminth co-infection might suppress the host immune responses and

-p

consequently could increase the severity of other infectious diseases, including COVID-19, and

lP

re

mitigate vaccine efficacy [4,5,11].
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Helminthiases are among the most common infectious diseases in developing countries and are
in a synergistic epidemic, called syndemic [14,15]; several pathogens could infect individuals,

ur

and COVID-19-helminth syndemic in these areas may be a common possibility, not yet studied

Jo

and understood enough [16]. The effects of these pathogens on COVID-19 vaccines efficacy
must be considered during the current deployment of the mass use of COVID-19 vaccines in
these endemic regions, ideally before. For instance, Schistosoma infections decrease the efficacy
of vaccines against tuberculosis or tetanus (toxoid) [17]; lower levels of INF-γ and higher levels
of IL-10 and TGF-β in individuals co-infected with Plasmodium, Ascaris lumbricoides, and
hookworms, as compared to those infected only by Plasmodium, have been observed [18];
experimentally, in mice, helminth infections reduced the quantity and quality of antibody
responses to vaccination against seasonal influenza [19], and diminished the strong immunity
induced by blood-stage antigens against Plasmodium chabaudi [20].

5

Before or concurrently with the mass use of COVID-19 vaccines in endemic helminth areas,
public health strategic planning to decrease the helminth co-infection immunomodulatory effects
must be studied. Massive deworming [6,15], or several boosts to induce a T-cell help response,
and neutralizing antibodies as part of the adaptive immune response, such as immunemodulating therapies [21], human monoclonal antibody blocking SARS-CoV-2 infection [22],

ro

of

and the use of a specific adjuvant [23] have been suggested.

-p

Schistosoma infection is correlated with increased transmission of HIV and deworming with

re

decreased viral load, and improved CD4+ counts among HIV-infected individuals have been

lP

noted [15]. A single dose of 400 mg of albendazole before influenza immunization improved the

na

immune response; the treated group had higher levels of total antibodies [24]. Deworming can
decrease SARS-CoV-2 viral load and improve T cell CD8+ in the lung microenvironment [12].

ur

Before implementing the COVID-19 vaccines, mass deworming could be a pharmacological

Jo

intervention to improve anti-SARS-Cov-2 protection in helminth infected individuals, obviously
requiring studies and confirmation yet.

Due to its immunomodulatory, antioxidant, anti-inflammatory, and neuroprotective effects,
melatonin is a potential complement or therapeutic alternative to combat viral, bacterial, and
parasitic infections [25,26]. We coincide with the suggestion that this hormone should be
considered for studies at prophylactic use or treatment alone or in combination with other drugs
for COVID-19 to understand its usefulness in this context [27]. It has been demonstrated that
melatonin treatment enhances the efficiency of mice immunization against the Venezuelan

6
equine encephalomyelitis virus [28]. Therefore, the use of this hormone before implementing
programs of COVID-19 vaccination in helminths endemic areas should be studied since this
pharmacological intervention would improve the immune impact of vaccines. Melatonin would
be cheap and be an adjuvant during COVID-19 vaccination.

The possible implications of the immune regulation caused by helminth intestinal infections in

of

humans co-infected by SARS-CoV-2 are particularly worrisome in some countries of Latin

ro

America, such as is the case Venezuela, Honduras, Nicaragua, Peru, among others, since

-p

intestinal parasites constitute a serious and persistent public health problem in these nations. For

re

example, along decades in Venezuela, it has been observed high rates of parasitic infection with

lP

one or more species, up to 92%, and rates of Ascaris lumbricoides and Trichuris trichiura up to

na

74.6% and 82.8%, respectively, in impoverished communities [29-32].

ur

In the last two decades, the severe political, economic, and social crises in some countries have

Jo

triggered an unprecedented increasing humanitarian crisis. That is especially the case of
Venezuela. The rising trend of hyperinflation and food shortages have enhanced poverty and
malnutrition rates; 96% of households are in poverty and 79% in extreme indigence. The
malnutrition rate in children under five years of age from Venezuela is 8% [33]. This sequence
of events and the collapse of health systems and public services foster the prevalence,
transmission, and dynamic epidemiology of infectious agents. An increase in the prevalence of
multiple infectious diseases, re-emergence of controlled illnesses such as tuberculosis, cholera,
measles, diphtheria, malaria, yellow fever, and multiple outbreaks have been observed in

7
Venezuela the last two decades [34]. The whole immune balance status attributable to the
immune interaction between host and pathogens must be defined in the current scenario.

This complex epidemiological, sanitary, and poverty picture combined with the powerful
transmissibility and eventual severity of the infection by SARS-CoV-2 indicate the significant
risk of such populations suffering a more devastating impact of COVID-19 than people from

of

other regions. According to family wealth, education, and ethnic group, substantial inequalities

ro

in the prevalence of infection have been revealed in developing and industrialized countries

-p

[35,36]. COVID-19 pandemic is beating Latin American countries with intensity. It is more

re

complex at the poorest and disadvantaged groups [35]. Venezuela is currently the poorest

lP

country in this area and is ranked second in extreme poverty worldwide, only surpassed by

na

Nigeria in Africa [33].

ur

On the other hand, the several strategies that have been proposed to diminish helminths impact

Jo

over viral vaccination are not feasible in Venezuela due to its current economic collapse. The
situation in this country is incredibly distressing due to the collapse of the health systems, the
scarcity of medicines and care policies for seniors and the impoverished. It is conceivable that
COVID-19 morbidity and mortality in Venezuela could be high, and vaccines' immune impact is
affected. In the current scenario of this country, COVID-19-helminth syndemic may be a joint
likelihood, and the whole immune balance attributable to the immune interaction between host
and pathogens must be resolved [6,10,37,38].

The possible implications of the immune-regulation triggered by helminths in humans co-

8
infected by SARS-CoV-2 and its effects on the viral disease outcome and vaccination
effectiveness raise high expectations and questions that need to be determined and open new
avenues of investigation, particularly in tropical countries [6,10,37-40]. In conclusion, the
implications of the immunomodulation effect of helminths in endemic areas must be considered
in the context of COVID-19 mass vaccination.
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